Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Receivables: 2021-2024

Historic Receivables for Immunocore Holdings (IMCR) over the last 4 years, with Dec 2024 value amounting to $63.0 million.

  • Immunocore Holdings' Receivables rose 19.23% to $75.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $271.8 million, marking a year-over-year increase of 16.28%. This contributed to the annual value of $63.0 million for FY2024, which is 20.95% up from last year.
  • Latest data reveals that Immunocore Holdings reported Receivables of $63.0 million as of FY2024, which was up 20.95% from $52.1 million recorded in FY2023.
  • Immunocore Holdings' 5-year Receivables high stood at $63.0 million for FY2024, and its period low was $7.3 million during FY2021.
  • For the 3-year period, Immunocore Holdings' Receivables averaged around $49.6 million, with its median value being $52.1 million (2023).
  • Data for Immunocore Holdings' Receivables shows a peak YoY soared of 357.92% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows Immunocore Holdings' Receivables stood at $7.3 million in 2021, then soared by 357.92% to $33.6 million in 2022, then soared by 55.11% to $52.1 million in 2023, then rose by 20.95% to $63.0 million in 2024.